FY2023 EPS Estimates for First Wave BioPharma, Inc. Boosted by Analyst (NASDAQ:FWBI)Ticker Report • 28 days ago
First Wave BioPharma, Inc. (NASDAQ:FWBI Free Report) HC Wainwright boosted their FY2023 earnings estimates for shares of First Wave BioPharma in a report released on Monday, March...
Share to Feed
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
First Wave BioPharma acquires ImmunogenX, focusing on advancing GI pipeline. James Sapirstein remains Chairman & CEO, with Jack Syage as President & COO.'
read more...
Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease James Sapirstein, Chairman and Chief Executive Officer, to continue leading First Wave...
BOCA RATON, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), ( First Wave BioPharma or the Company ), a clinical-stage biopharmaceutical company specializing...
BOCA RATON, Fla., March 04, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), ( First Wave BioPharma or the Company ), a clinical-stage biopharmaceutical company specializing...
BOCA RATON, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), ( First Wave BioPharma or the Company ), a clinical-stage biopharmaceutical company specializing in...
Shares of First Wave BioPharma, Inc. (NASDAQ:FWBI Get Free Report) traded down 3% during mid-day trading on Thursday . The company traded as low as $4.95 and last traded at $5.14. 159,133...
BOCA RATON, Fla., Jan. 23, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), ( First Wave BioPharma or the Company ), a clinical-stage biopharmaceutical company specializing in...
BOCA RATON, Fla., Jan. 17, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), ( First Wave BioPharma or the Company ), a clinical-stage biopharmaceutical company specializing in...